Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial.

• Main Authors: Allan Musinguzi (Author), Joan R Kasidi (Author), Jillian L Kadota (Author), Fred Welishe (Author), Anne Nakitende (Author), Lydia Akello (Author), Jane Nakimuli (Author), Lynn T Kunihira (Author), Bishop Opira (Author), Yeonsoo Baik (Author), Devika Patel (Author), Amanda Sammann (Author), Christopher A Berger (Author), Hélène E Aschmann (Author), Payam Nahid (Author), Robert Belknap (Author), Moses R Kamya (Author), Margaret A Handley (Author), Patrick P J Phillips (Author), Noah Kiwanuka (Author), Achilles Katamba (Author), David W Dowdy (Author), Adithya Cattamanchi (Author), Fred C Semitala (Author), Anne R Katahoire (Author)
• Format: Knjiga
• Izdano: Public Library of Science (PLoS), 2024-01-01T00:00:00Z.
• Teme: article
• Online dostop: Connect to this object online.

Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify factors influencing successful 3HP delivery. We conducted a qualitative assessment of 3HP...